Overview

Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis

Status:
Not yet recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

The pharmacodynamic endpoint of percentage of subjects with suppressed estradiol level (less than 20 pg/mL) on cycle day 29 is the primary endpoint of the study.

Phase:

Phase 2

Details

Lead Sponsor:

Enteris BioPharma Inc.

Collaborators:

Parexel
Syneos Health

Treatments:

Leuprolide